Gefitinib circumvents hypoxia-induced drug resistance by the modulation of HIF-1 alpha
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Rho, Jin Kyung | - |
dc.contributor.author | Choi, Yun Jung | - |
dc.contributor.author | Lee, Jin Kyung | - |
dc.contributor.author | Ryoo, Baek-Yeol | - |
dc.contributor.author | Il Na, Im | - |
dc.contributor.author | Yang, Sung Hyun | - |
dc.contributor.author | Kim, Cheol Hyeon | - |
dc.contributor.author | Do Yoo, Young | - |
dc.contributor.author | Lee, Jae Cheol | - |
dc.date.accessioned | 2021-09-08T19:14:20Z | - |
dc.date.available | 2021-09-08T19:14:20Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2009-03 | - |
dc.identifier.issn | 1021-335X | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/120458 | - |
dc.description.abstract | Hypoxia-inducible factor-1 alpha (HIF-1 alpha) is a transcriptional factor which is activated by hypoxia and associated with cell survival, proliferation and drug resistance. Recent studies have shown that the down-stream molecules of the epidermal growth factor receptor (EGFR) signal are involved in the hypoxia-dependent or -independent HIF-1 alpha protein accumulation. Thus, we hypothesized that an EGFR-TK inhibitor, gefitinib, might circumvent the hypoxia-induced drug resistance via the regulation of HIF-1 alpha expression. In our data, treatment of gefitinib suppressed induced HIF-alpha by hypoxia. This action of gefitinib was caused by reduced protein stability without any change in the level of HIF-1 alpha mRNA. The effect of gefitinib on down-regulation of HIF-1 alpha was reversed by transfection of constitutively active form of Akt. The cellular response to gefitinib was similar in both normoxia and hypoxia condition. However, the response to conventional chemotherapeutic drugs decreased > 50% under hypoxia condition and they did not change HIF-1 alpha expression. In addition, the suppression of HIF-1 alpha using siRNA overcame partially hypoxia-induced drug resistance. In conclusion, gefitinib was able to circumvent hypoxia-induced drug resistance suggesting that the effective suppression of HIF-1 alpha by the inhibition of EGFR-Akt pathway may overcome the hypoxia-induced drug resistance. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPANDIDOS PUBL LTD | - |
dc.subject | EPIDERMAL-GROWTH-FACTOR | - |
dc.subject | INDUCIBLE FACTOR 1-ALPHA | - |
dc.subject | UNFAVORABLE PROGNOSIS | - |
dc.subject | SIGNALING PATHWAY | - |
dc.subject | FACTOR RECEPTOR | - |
dc.subject | CANCER CELLS | - |
dc.subject | EXPRESSION | - |
dc.subject | FACTOR-1-ALPHA | - |
dc.subject | OVEREXPRESSION | - |
dc.subject | ACTIVATION | - |
dc.title | Gefitinib circumvents hypoxia-induced drug resistance by the modulation of HIF-1 alpha | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Do Yoo, Young | - |
dc.identifier.doi | 10.3892/or_00000287 | - |
dc.identifier.scopusid | 2-s2.0-64849102022 | - |
dc.identifier.wosid | 000263584000030 | - |
dc.identifier.bibliographicCitation | ONCOLOGY REPORTS, v.21, no.3, pp.801 - 807 | - |
dc.relation.isPartOf | ONCOLOGY REPORTS | - |
dc.citation.title | ONCOLOGY REPORTS | - |
dc.citation.volume | 21 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 801 | - |
dc.citation.endPage | 807 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | EPIDERMAL-GROWTH-FACTOR | - |
dc.subject.keywordPlus | INDUCIBLE FACTOR 1-ALPHA | - |
dc.subject.keywordPlus | UNFAVORABLE PROGNOSIS | - |
dc.subject.keywordPlus | SIGNALING PATHWAY | - |
dc.subject.keywordPlus | FACTOR RECEPTOR | - |
dc.subject.keywordPlus | CANCER CELLS | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | FACTOR-1-ALPHA | - |
dc.subject.keywordPlus | OVEREXPRESSION | - |
dc.subject.keywordPlus | ACTIVATION | - |
dc.subject.keywordAuthor | gefitinib | - |
dc.subject.keywordAuthor | epidermal growth factor receptor | - |
dc.subject.keywordAuthor | hypoxia | - |
dc.subject.keywordAuthor | hypoxia-inducible factor-1 alpha | - |
dc.subject.keywordAuthor | lung cancer | - |
dc.subject.keywordAuthor | resistance | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.